Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2023-11-09 Report Publication Anno…
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Nykode Therapeutics – invitation to Q3 2023 financial results presentation
Report Publication Announcement Classification · 98% confidence The document is a short announcement titled "Company Announcement" from Nykode Therapeutics. It explicitly states that the company "will release its third quarter 2023 financial results before the opening of financial markets on Wednesday, November 15, 2023." It then provides details for a subsequent webcast presentation and Q&A session. Crucially, it directs the reader to the website to access the actual financial report. According to Rule #2 (The "MENU VS MEAL" Rule), a short document announcing the publication of a report, rather than being the report itself, should be classified as a Report Publication Announcement (RPA). The document is short (3190 chars) and serves only to announce the upcoming release of the Q3 2023 financial results and associated webcast.
2023-11-09 English
Nykode Therapeutics – invitation to Q3 2023 financial results presentation
Report Publication Announcement Classification · 98% confidence The document is titled 'Nykode Therapeutics – invitation to Q3 2023 financial results presentation'. It explicitly states that the company 'will release its third quarter 2023 financial results' on a future date (November 15, 2023) and announces a subsequent webcast presentation. The document itself is an announcement about the upcoming release of financial results and the associated call, not the full results document (like an IR or ER) or the transcript of the call. Since it is announcing the publication of a report and providing details for the associated call/presentation, it fits the description of a Report Publication Announcement (RPA), which signals the release of other materials. The document length (3076 chars) is also short, supporting the RPA classification over the full report classification.
2023-11-09 English
Nykode Therapeutics to Present at Jefferies Healthcare Conference
Report Publication Announcement Classification · 99% confidence The document is a short announcement from Nykode Therapeutics stating that its CEO will present at the '2023 Jefferies Healthcare Conference' on a specific date and time. It also mentions that the presentation slides will be made available on the company website. This is not a full financial report (like 10-K or IR), nor is it a transcript (CT) or a formal regulatory filing about share transactions or dividends. It is an announcement about participation in an investor event, which falls under general investor relations communication. Since there is no specific category for 'Conference Presentation Announcement,' and it is an announcement about investor-facing material, it is best classified as a general Investor Presentation (IP) announcement or, more broadly, a Regulatory Filing (RNS) if the intent is to disseminate material non-public information broadly. However, given the context of investor events, it is most closely related to the dissemination of investor materials. Since the document itself is the announcement of participation, and not the presentation slides, and it doesn't fit the specific definitions of ER, DIV, or CAP, the most appropriate category for an announcement regarding an upcoming investor presentation is often RNS (Regulatory Filings) if it's a mandatory disclosure, or IP if the focus is on the material being presented. Given the nature of conference presentations being a key part of investor engagement, and the document being a brief announcement, RNS is the safest fallback for general corporate updates that don't fit the highly specific financial/structural categories. However, since the content is about an upcoming presentation, which is a form of investor communication, and it's not a formal financial report, RNS is the most suitable general category for such an announcement.
2023-11-07 English
Nykode Therapeutics to Present at Jefferies Healthcare Conference
Regulatory Filings Classification · 95% confidence The document is a short press release announcing that the CEO of Nykode Therapeutics will present at the '2023 Jefferies Healthcare Conference' on a specific date and time. It also mentions that presentation slides will be made available on the company's website. This is not a full financial report (like 10-K or IR), nor is it a formal regulatory filing about share transactions or dividends. It is an announcement regarding the company's participation in an investor event, which falls under general investor relations communication. Since there is no specific category for 'Conference Presentation Announcement,' and it is not a formal report, the most appropriate classification is 'Regulatory Filings' (RNS) as a general investor communication, although 'Investor Presentation' (IP) might seem close, this document is *announcing* the presentation, not providing the presentation itself. Given the context of investor relations announcements that don't fit other specific categories, RNS is the best fit, or potentially a general Investor Relations announcement if one existed. However, based on the provided definitions, RNS serves as the general regulatory/investor announcement fallback.
2023-11-07 English
Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider
Director's Dealing Classification · 100% confidence The document details a transaction involving a person discharging managerial responsibilities (Michael Engsig, CEO) at Nykode Therapeutics ASA. Specifically, it reports the 'Acquisition of shares' including the price, volume, date (31.10.2023), and the exchange (XOSL - Oslo Stock Exchange). This structure precisely matches the definition of a Director's Dealing report, which tracks personal share transactions by company directors and executives (insider trades). This corresponds to the filing code DIRS.
2023-10-31 English
Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider
Major Shareholding Notification Classification · 99% confidence The document explicitly states it is a 'Mandatory notification of acquisition of shares by primary insider' involving the CEO acquiring shares. This directly corresponds to the definition of Director's Dealing (insider trades). The filing type code for Director's Dealing is DIRS.
2023-10-31 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.